DePuy Synthes licenses LifeNet Health's cellular allograft

DePuy Synthes enters a worldwide deal to market LifeNet Health's new cellular allograft technology, boosting the company's biomaterial portfolio.

Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes entered a licensing deal with LifeNet Health for the bio-implant maker's new cellular allograft.

News Well, Biotech , Deals Roundup, Spinal

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1fyme1Z